An Interventional Study of Infigratinib in Children With Hypochondroplasia

PHASE2/PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Hypochondroplasia
Interventions
DRUG

infigratinib 0.128 mg/kg/day

Oral infigratinib 0.128 mg/kg/day

DRUG

infigratinib 0.25 mg/kg/day

Oral infigratinib 0.25 mg/kg/day

Trial Locations (22)

3052

Murdoch Children's Research Institute, Parkville

5021

Haukeland University Hospital, Bergen

17164

Astrid Lindgren Children's Hospital, Solna

20010

Children's National Hospital, Washington D.C.

21287

Johns Hopkins School of Medicine, Baltimore

31059

Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital des Enfants, Toulouse

37232

Vanderbilt University Medical Center, Nashville

53705

University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic, Madison

65201

University of Missouri, Columbia

69677

Hôpital Femme Mère Enfant, Bron

75015

Hôpital Universitaire Necker-Enfants Malades, Paris

80045

Childrens Hospital Colorado, Aurora

94609

UCSF Benioff Children's Hospital, Oakland

229899

KK Women's and Children's Hospital, Singapore

N6C 2R5

London Health Services Center - Children's Hospital of Western Ontario, London

K1H 8L1

Children's Hospital of Eastern Ontario Research Institute, Ottawa

H3T 1C5

Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine, Montreal

0372

Paediatric Clinical Research Unit at Osla University Hospital, Oslo

3000-602

Hospital Pediátrico de Coimbra, Coimbra

01008

Hospital Vithas San Jose, Vitoria-Gasteiz

M13 9WL

Manchester University, Manchester

S10 2TH

Sheffield Children's Hospital, Sheffield

All Listed Sponsors
lead

QED Therapeutics, Inc., a Bridgebio company

INDUSTRY